Bradykinin preconditioning induces protective effects on the spinal cord ischemic injury of rats.
The study was performed to investigate the effects of bradykinin preconditioning on spinal cord ischemic injury using an in vivo transient spinal cord ischemia model in rats. Prior to ischemia, bradykinin was infused continuously via the left femoral artery starting 15min before ischemia. Neurological functions were evaluated for 7 days postoperatively using modified Tarlov's scores. Tarlov's score outcomes showed a marked improvement in the bradykinin group compared to the ischemia group. The blood-spinal cord barrier (BSCB) permeability was also decreased by bradykinin preconditioning after 72 h reperfusion focal spinal cord in rats, which was greatly reversed by B9430 (bradykinin B2 receptor antagonist). Immunohistochemical and Western blot analysis of spinal cords revealed a significant increase in basic fibroblast growth factor protein (bFGF) levels. The study demonstrated that bradykinin preconditioning induces protection against spinal cord ischemic injury, and this protection is likely due to the protection of the vasculature of the spinal cord and the promotion of neuronal survival.
Yan-Feng
Wang
W
Department of Orthopaedics, The First Affiliated Hospital, China Medical University, Shen Yang 110001, Liaoning Province, PR China. wyf2007888@yahoo.com.cn
Gang
Lv
L
Yan-Ting
Gu
G
D000704:Analysis of Variance; D000818:Animals; D001920:Bradykinin / Q000008:administration & dosage* / Q000031:analogs & derivatives; D065168:Bradykinin Receptor Antagonists; D004195:Disease Models, Animal; D016222:Fibroblast Growth Factor 2 / Q000378:metabolism; D007839:Functional Laterality; D005786:Gene Expression Regulation / Q000187:drug effects / Q000502:physiology; D007511:Ischemia / Q000150:complications; D019194:Ischemic Preconditioning / Q000379:methods*; D008297:Male; D011897:Random Allocation; D051381:Rats; D017207:Rats, Sprague-Dawley; D013119:Spinal Cord Injuries / Q000209:etiology / Q000517:prevention & control*; D013667:Technetium; D014665:Vasodilator Agents / Q000008:administration & dosage*
C121351:B 9430; D065168:Bradykinin Receptor Antagonists; D014665:Vasodilator Agents; D016222:Fibroblast Growth Factor 2; D013667:Technetium; D001920:Bradykinin